Literature DB >> 3258413

Malignant prolactinoma with multiple intracranial metastases studied with positron emission tomography.

C Muhr1, M Bergström, P O Lundberg, M Hartman, K Bergström, L Pellettieri, B Långström.   

Abstract

A rare case of a patient with multiple intracranial metastases from a prolactin-secreting pituitary neoplasm is described. At the age of 14 years, the patient had been operated on for a sellar tumor; he presented 12 years later with severe headache, at which time computed tomographic and magnetic resonance imaging scans revealed multiple intracranial metastases. Histopathology examination showed pituitary neoplastic cells with positive immunostaining for prolactin. The patient was investigated with positron emission tomography (PET) and dopamine D2-receptor binding, and the amino acid metabolism of the tumor was characterized in vivo. High dopamine D2-receptor binding and high amino acid metabolism were found in the tumor. The patient was subsequently treated with bromocriptine injections that resulted in a decrease in serum prolactin levels, decreased dopamine D2-receptor binding, reduced amino acid metabolism, and a reduction in tumor volume. This case demonstrates a beneficial effect of bromocriptine treatment in a patient with prolactinoma with multiple intracranial metastases. It also illustrates the great potential of PET in the in vivo characterization of the D2-binding and the high sensitivity of 11C-labeled L-methionine in the follow-up of treatment in patients with pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258413     DOI: 10.1227/00006123-198802000-00017

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  9 in total

Review 1.  Malignant pituitary tumours.

Authors:  G A Kaltsas; A B Grossman
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

Review 2.  Positron emission tomography applied in the study of pituitary adenomas.

Authors:  C Muhr; M Bergström
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

Review 3.  Progression on metastatic neuroendocrine carcinoma from a recurrent prolactinoma: a case report.

Authors:  M Sironi; G Cenacchi; L Cozzi; G Tonnarelli; M Iacobellis; D Treré; A Assi
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

Review 4.  Pituitary carcinoma: diagnosis and treatment.

Authors:  M Beatriz S Lopes; Bernd W Scheithauer; David Schiff
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 5.  Imaging in neurooncology.

Authors:  Andreas H Jacobs; Lutz W Kracht; Axel Gossmann; Maria A Rüger; Anne V Thomas; Alexander Thiel; Karl Herholz
Journal:  NeuroRx       Date:  2005-04

6.  Dopaminergic resistance in a case of invasive macroprolactinoma.

Authors:  D Schwarzstein; A García-Patterson; G Giménez; J Calaf; M Puig-Domingo; A Caixàs; X Matías-Guiu; S M Webb
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

7.  Malignant prolactinoma with craniospinal metastasis in a 12-year-old boy.

Authors:  Abel Po-Hao Huang; Shih-Hung Yang; Chi-Cheng Yang; Meng-Fai Kuo; Mu Zon Wu; Yong-Kwang Tu
Journal:  J Neurooncol       Date:  2008-07-12       Impact factor: 4.130

8.  Prolactin secreting pituitary carcinoma.

Authors:  T Petterson; I A MacFarlane; J M MacKenzie; M D Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

9.  Pituitary Carcinomas.

Authors:  Wolfgang Saeger; Dorothee Lubke
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.